Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development in autoimmune disease; pivotal trial for Waldenstrom macroglobulinemia (WM) is expected to initiate in the... Read More